European Archives - Page 114 of 1534 - European Medical Journal

More Than One Million People to be Offered Semaglutide on NHS

Semaglutide is set to be offered to more than one million people with cardiovascular disease on the NHS in coming months.

Eli Lilly office building

Lilly’s weight loss pill wins FDA approval

Eli Lilly won FDA approval on 1 April 2026 for a once-daily oral GLP-1, orforglipron.

Urinary Metabolites Identify Bladder Cancer and Predict Recurrence

Urinary metabolites may help detect bladder cancer and predict recurrence, offering a potential non-invasive tool to improve patient monitoring and outcomes.

New Trial Shows TENS Improves Pain in Fibromyalgia

Cluster trial shows TENS improves fibromyalgia pain with meaningful reductions sustained over six months and high patient satisfaction rates.

RAS inhibitors: risks after eGFR decline - EMJ

Stopping RAS Inhibitors After eGFR Fall May Increase Risk

Stopping RAS inhibitors after an eGFR decline may increase risk of kidney failure and death, according to a large cohort study.

Rapid Test Detects Acute Respiratory Distress Syndrome Subtypes

Rapid testing identifies acute respiratory distress syndrome subtypes linked to mortality, supporting precision medicine in critical care.

Umbilical Cord Antiseptics May Reduce Neonatal Mortality

Topical application of 4.0% chlorhexidine to the umbilical cord may reduce neonatal mortality in low- and middle-income countries, a 2026 review has found.

GI Challenges in Parkinson’s Disease

Parkinson’s disease (PD) affects at least 1% of people aged over 60 years and 2–3% of those aged over 65 years. PD is reported to be the…

World map with the Middle East highlight with a red glowing dot

Supply chains and trials hit by Middle East instability

Pharma companies are facing renewed pressure due to instability linked to the Middle East conflict.

Integrated Genomic Model Improves CAD Risk Prediction

The model identified approximately 13% of high-risk individuals who would not have been detected using polygenic risk scores alone.